Conference For Journalists On Impotence

October 22, 1998

October 20, 1998

Memo To: Health, Medical, and Science Journalists

From: Bill Glitz

Subject: Conference For Medical, Health, And Science Journalists On Emerging Medical And Scientific Information On Impotence

Ever since the FDA approval of Viagra this past spring, impotence has received extensive and intensive ongoing coverage in the media. Since that watershed event in March and the reporting of new research data at the American Urological Association Annual Meeting in June, major new developments have occurred regarding the diagnosis and treatment of impotence.

In order to update editors and reporters on new developments and emerging scientific information regarding impotence, the American Foundation for Urologic Disease (AFUD) and NIH's National Institute of Diabetes and Digestive and Kidney Disease have scheduled an update conference for journalists reviewing the latest medical and scientific information on impotence. The conference will take place on the NIH campus in Bethesda on Monday, October 26 beginning at 8 a.m. with registration and a continental breakfast. It will be held in Conference Room 6C10 on the sixth floor of Building 31. The first session will start at 8:30 a.m. and the last presentation is scheduled to end at 3:30 p.m.

Conference participants include several of the leading experts on impotence from United States and several other countries.

Some of the topics to be addressed include: This conference also will set the stage for International Impotence Education Month, which will take place throughout November. Information presented during the October 26 NIH conference will provide a variety of new story opportunities regarding the treatment of impotence.

If you would like additional information prior to the conference, contact Bill Glitz at (703) 532-3797.

NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to